ERBIN:: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor

被引:256
|
作者
Borg, JP
Marchetto, S
Le Bivic, A
Ollendorff, V
Jaulin-Bastard, F
Saito, H
Fournier, E
Adélaïde, J
Margolis, B
Birnbaum, D
机构
[1] INSERM, U119, F-13009 Marseille, France
[2] Fac Sci Luminy, IBDM, F-13288 Marseille 09, France
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
[4] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA
关键词
D O I
10.1038/35017038
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The ERBB receptors have a crucial role in morphogenesis and oncogenesis. We have identified a new PDZ protein we named ERBIN (ERBB2 interacting protein) that acts as an adaptor for the receptor ERBB2/HER2 in epithelia. ERBIN contains 16 leucine-rich repeats (LRRs) in its amino terminus and a PDZ (PSD-95/DLG/ZO-1) domain at its carboxy terminus, and belongs to a new PDZ protein family. The PDZ domain directly and specifically interacts with ERBB2/ HER2. ERBIN and ERBB2/HER2 colocalize to the lateral membrane of human intestinal epithelial cells. The ERBIN-binding site in ERBB2/HER2 has a critical role in restricting this receptor to the basolateral membrane of epithelial cells, as mutation of the ERBIN-binding site leads to the mislocalization of the receptor in these cells. We suggest that ERBIN acts in the localization and signalling of ERBB2/HER2 in epithelia.
引用
收藏
页码:407 / 414
页数:8
相关论文
共 50 条
  • [21] Essential roles of Her2/erbB2 in cardiac development and function
    Negro, A
    Brar, BK
    Lee, KF
    RECENT PROGRESS IN HORMONE RESEARCH, VOL 59: CARDIOVASCULAR ENDOCRINOLOGY & OBESITY, 2004, 59 : 1 - 12
  • [22] Single Domain Monoclonal Antibody Specific for Her2 or ERBB2
    Omidfar, Kobra
    HYBRIDOMA, 2011, 30 (01): : 105 - 105
  • [23] Treatment options in ErbB2 (HER2)-overexpressing breast cancer
    Jackisch, Christian
    BREAST CARE, 2008, 3 : 1 - 1
  • [24] ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
    Sunil K. Joshi
    Jamie M. Keck
    Christopher A. Eide
    Daniel Bottomly
    Elie Traer
    Jeffrey W. Tyner
    Shannon K. McWeeney
    Cristina E. Tognon
    Brian J. Druker
    Leukemia, 2020, 34 : 2798 - 2804
  • [25] Challenges in the treatment of ErbB2 (HER2)-positiive breast cancer
    Jackisch, Christian
    EJC SUPPLEMENTS, 2008, 6 (05): : 7 - 14
  • [26] PRACTICE ADVANCES ERBB2 (HER2) Alterations in Colorectal Cancer
    Roy-Chowdhuri, Sinchita
    Davies, Kurtis D.
    Ritterhouse, Lauren L.
    Snow, Anthony N.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (10): : 1064 - 1066
  • [27] HER2 therapy - HER2 (ERBB2): functional diversity from structurally conserved building blocks
    Landgraf, Ralf
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [28] Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
    Reid, Alison
    Vidal, Laura
    Shaw, Heather
    de Bono, Johann
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (03) : 481 - 489
  • [29] ERBB2 oncogenicity: ERBIN helps to perform the job
    Mei, Lin
    Borg, Jean-Paul
    MOLECULAR & CELLULAR ONCOLOGY, 2015, 2 (03):
  • [30] ErbB2 (HER2)-positives MammakarzinomResistenzmechanismenErbB2 (HER2) positive breast cancer Mechanisms of resistance
    K. Kast
    W. Distler
    Der Gynäkologe, 2010, 43 (7): : 574 - 578